The trial did not achieve statistical significance on either of its primary goals — cognition and activities of daily living, the company said in a statement.

Myriad, which spent about $60 million on development of Flurizan during the 2008 financial year, said remaining expenses to wrap up the drug program are expected to be about $8 million, spread primarily over the next two quarters.